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Our independent cohort studies have consistently shown the reduction of the nuclear receptor 
RORA (retinoic acid-related orphan receptor-alpha) in lymphoblasts as well as in brain 
tissues from individuals with autism spectrum disorder (ASD). Moreover, we have found that 
RORA regulates the gene for aromatase, which converts androgen to estrogen, and that male 
and female hormones regulate RORA in opposite directions, with androgen suppressing 
RORA, suggesting that the sexually dimorphic regulation of RORA may contribute to the 
male bias in ASD. However, the molecular mechanisms through which androgen and 
estrogen differentially regulate RORA are still unknown. 
Methods 
Here we use functional knockdown of hormone receptors and coregulators with small 
interfering RNA (siRNA) to investigate their involvement in sex hormone regulation of 
RORA in human neuronal cells. Luciferase assays using a vector containing various RORA 
promoter constructs were first performed to identify the promoter regions required for inverse 
regulation of RORA by male and female hormones. Sequential chromatin 
immunoprecipitation methods followed by quantitative reverse transcriptase-polymerase 
chain reaction (qRT-PCR) analyses of RORA expression in hormone-treated SH-SY5Y cells 
were then utilized to identify coregulators that associate with hormone receptors on the 
RORA promoter. siRNA-mediated knockdown of interacting coregulators was performed 
followed by qRT-PCR analyses to confirm the functional requirement of each coregulator in 
hormone-regulated RORA expression. 
Results 
Our studies demonstrate the direct involvement of androgen receptor (AR) and estrogen 
receptor (ER) in the regulation of RORA by male and female hormones, respectively, and 
that the promoter region between −10055 bp and −2344 bp from the transcription start site of 
RORA is required for the inverse hormonal regulation. We further show that AR interacts 
with SUMO1, a reported suppressor of AR transcriptional activity, whereas ERα interacts 
with the coactivator NCOA5 on the RORA promoter. siRNA-mediated knockdown of 
SUMO1 and NCOA5 attenuate the sex hormone effects on RORA expression. 
Conclusions 
AR and SUMO1 are involved in the suppression RORA expression by androgen, while ERα 
and NCOA5 collaborate in the up-regulation of RORA by estrogen. While this study offers a 
better understanding of molecular mechanisms involved in sex hormone regulation of RORA, 
it also reveals another layer of complexity with regard to gene regulation in ASD. Inasmuch 
as coregulators are capable of interacting with a multitude of transcription factors, aberrant 
expression of coregulator proteins, as we have seen previously in lymphoblasts from 
individuals with ASD, may contribute to the polygenic nature of gene dysregulation in ASD. 
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Background 
Autism spectrum disorder (ASD) is a neurodevelopmental disorder characterized by deficits 
in social understanding and interactions, aberrant communication, and repetitive, stereotyped 
behaviors, often with restricted interests [1,2]. Although the male-to-female ratios of ASD 
reported by different epidemiological studies are different depending on the populations 
studied [3-5], the prevalence of ASD is consistently higher in males than females, prompting 
theories that fetal or perinatal exposure to elevated levels of male hormones may increase 
susceptibility toward autism [6]. There is increasing evidence linking elevated fetal 
testosterone levels in amniotic fluid to autistic symptomatology [7,8] as well as morphology 
of the corpus callosum and sexually dimorphic brain regions [9,10]. Moreover, we have 
identified deregulated genes involved in androgen biosynthesis as well as higher testosterone 
levels in lymphoblastoid cell lines (LCL) from individuals with autism relative to their 
respective unaffected sex-matched siblings [11], further implicating a role for sex hormones 
in ASD, but there is still no clear understanding of the molecular mechanisms through which 
the sex hormones may play a role in autism susceptibility. 
We have recently identified RORA as a novel candidate gene for ASD [12]. RORA encodes 
retinoic acid-related (RAR) orphan receptor-alpha, which is a ligand-dependent nuclear 
receptor that regulates gene transcription by binding to specific DNA response elements 
consisting of the consensus (A/G)GGTCA core motif in the regulatory region of target genes 
[13,14]. Our recent studies have demonstrated: reduced expression of RORA in LCL derived 
from individuals with autism [15]; increased methylation leading to reduced expression of 
RORA in the LCL from cases vs. sibling controls [12]; and decreased expression of RORA 
protein in the prefrontal cortex and the cerebellum of individuals with autism [12,16]. 
Together, these results link these molecular changes in RORA in blood-derived peripheral 
cells to molecular pathology in the brain tissues of individuals with ASD. 
Studies using the Rora-deficient staggerer mouse model show that Rora is involved in 
several processes relevant to ASD, including Purkinje cell differentiation [17,18], cerebellar 
development [19,20], protection of neurons against oxidative stress [21], suppression of 
inflammation [22], and regulation of circadian rhythm [23]. Indeed, cerebellar abnormalities 
[24], including the loss of Purkinje cells [25], have been reported in autism, and the brain 
tissues of individuals with ASD show evidence of inflammation [26], as well as oxidative 
stress [27]. Moreover, there is increasing awareness of sleep disturbances in ASD [28-31], 
and genetic studies as well as our gene expression study of different subtypes of ASD have 
implicated a role for circadian rhythm regulator genes in ASD [15,32,33]. Behavioral studies 
on the staggerer mouse, primarily used as a model to study ataxia and dystonia [19], further 
show that these Rora-deficient mice also exhibit restricted behaviors reminiscent of autism, 
such as perseverative tendencies [34], limited maze patrolling [35], anomalous object 
exploration [36], as well as deficits in spatial learning [37]. Although there are currently no 
reported studies connecting social behaviors with Rora deficiency in mice, it is clear that 
RORA is associated with at least some of the symptomatology and pathology of ASD. 
Recently, we found that RORA transcriptionally regulates multiple ASD-related genes, 
including A2BP1, CYP19A1, HSD17B10, ITPR1, NLGN1, and NTRK2, and reduced RORA 
expression leads to downregulation of these genes in human neuronal cells [38]. CYP19A1 
and HSD17B10 respectively code for aromatase and hydroxysteroid (17β) dehydrogenase, 
which are enzymes responsible for the conversion of androgens to estradiol. Downregulation 
of either of these genes can lead to increased androgen and decreased estrogen, either of 
which may have a negative impact on brain development [39-41]. Our recent studies have 
further shown that CYP19A1 and HSD17B10 expression levels, as well as those of the other 
four confirmed gene targets of RORA, are significantly reduced in the frontal cortex of 
RORA-deficient autistic subjects relative to sex- and age-matched controls, and that 
aromatase protein levels are strongly correlated with RORA protein levels in the brain 
[16,38]. 
In addition to our finding that RORA regulates the transcription of genes involved in the 
enzymatic conversion of male to female hormones, neurohistological studies by other groups 
have reported that loss of Purkinje neurons in male Rora-deficient staggerer mice occurs 
much earlier in life in comparison to female staggerer mice [42,43], revealing a sexually 
dimorphic response to Rora deficiency. We recently demonstrated that male and female sex 
hormones inversely regulate RORA expression in human neuronal cells by suppressing and 
enhancing RORA expression, respectively [16]. These observations suggest that the pathology 
associated with RORA deficiency may be manifested in a sexually dimorphic manner which, 
in turn, may be related to the sex bias in ASD. 
We have previously demonstrated hormone-mediated recruitment of androgen receptor (AR) 
and estrogen receptor alpha (ERα) to their respective binding sites on the RORA promoter 
[16]. Here we sought to determine whether AR and ERα are functionally involved in the 
regulation of RORA. Moreover, as it is known that hormone receptors must interact with 
other proteins (coregulators) to regulate transcription of their targets, we also sought to 
investigate the involvement of selected coregulator proteins in sex hormone-mediated 
regulation of RORA in human neuronal cells, with a focus on four coregulator proteins that 
were previously found to be differentially expressed in ASD [15]. 
Methods 
Cell culture 
The human neuroblastoma cells SH-SY5Y (ATCC, Manassas, VA, USA) were cultured in 
1:1 MEM and Ham’s F12 media (Mediatech, Manassas, VA, USA) supplemented with 15% 
(v/v) fetal bovine serum (Atlanta Biologicals, Lawrenceville, GA, USA) and 1% 
penicillin/streptomycin (P/S; Mediatech). Cells were maintained at 37°C with 5% CO2, and 
split 1:2 every 3 to 4 days when the cells reached approximately 80% confluency. For 
harvesting, the cells were treated with trypsin-ethylenediaminetetraacetic acid (EDTA) 
(Mediatech) for 2 to 3 minutes to release them from the surface of the culture flask. Complete 
growth medium was then added to the flask containing suspension cells to inactivate trypsin. 
Cells were transferred to a sterile centrifuge tube and pelleted by spinning at 800 rpm for 5 
minutes at 4°C and gently washed twice with ice-cold PBS. This study did not involve any 
human subjects or biomaterials taken from human subjects, and thus no ethical approval was 
required. 
Hormone treatment 
For hormone treatment, SH-SY5Y cells were cultured in culture flasks until the cultures 
became approximately 80% confluent. Confluent cells were carefully washed twice with 
phenol red-free 1:1 DMEM/F12 media (Mediatech) supplemented with 15% charcoal 
dextran-treated serum (Atlanta Biologicals) and 1% P/S, and then cultured in the phenol red-
free medium for 24 hours. Lyophilized 4,5α-dihydrotestosterone (DHT; Sigma-Aldrich, St. 
Louis, MO, USA) and 17β-estradiol (E2; Sigma-Aldrich) were diluted with molecular 
biology grade absolute ethanol (Fisher Scientific, Pittsburgh, PA, USA) to make 1 µM DHT 
or 1 µM E2 stock solutions. The stock solutions were further diluted with prewarmed 
complete phenol red-free culture medium to the desired final concentrations for hormone 
treatment and carefully added to the confluent cells. Cells were incubated in the hormone-
supplemented phenol red-free medium at 37°C with 5% CO2 for 2 hours. 
siRNA transfection 
siRNA-mediated knockdown of AR, ERα, SUMO1, or NCOA5 was conducted using 
Lipofectamine RNAiMAX transfection agent (Invitrogen, Carlsbad, CA, USA) according to 
the manufacturer’s protocol. Briefly, SH-SY5Y cells were cultured in complete growth 
medium without antibiotics in a 6-well culture plate. When cells were approximately 50% 
confluent, the medium was substituted with phenol red-free culture medium without 
antibiotics and the cells were further incubated for 24 hours. siRNA (Santa Cruz 
Biotechnology, Dallas, TX, USA) targeting AR, ERα, SUMO1, or NCOA5 (150 pmol) was 
diluted in 250 µl phenol red-free Opti-MEM I Reduced-Serum Medium (Invitrogen). 
Lipofectamine RNAiMAX (7.5 µl) was diluted in 250 µl phenol red-free Opti-MEM I 
reduced-serum medium in a separate tube. Then, the diluted siRNA and the diluted 
Lipofectamine RNAiMax were combined. The siRNA-Lipofectamine complex was incubated 
at room temperature for 5 minutes and added to the cells to a final siRNA concentration of 10 
nM. The cells were incubated for 24 hours and then treated with 1 nM DHT, 1 nM E2, or 
ethanol (vehicle), for 2 hours according to the aforementioned hormone treatment procedure 
before harvesting for subsequent analysis. The list of siRNAs is shown in Additional file 1. 
Transfection efficiency was assessed by qRT-PCR analysis (Additional file 2). 
Quantitative RT-PCR analysis 
Quantitative RT-PCR analyses were performed as described [11]. Total RNA from the cells 
was isolated using TRIzol (Invitrogen) and purified using the RNeasy Mini Kit (Qiagen, 
Valencia, CA, USA) following the manufacturers’ instructions. Human brain tissues were 
homogenized in the Bullet Blender Homogenizer (Next Advance, Averill Park, NY, USA) 
using nuclease-free glass beads, and total RNA was isolated from homogenized tissues using 
the RNeasy Mini Kit (Qiagen). RNA concentration was measured using a NanoDrop 1000 
spectrophotometer (Thermo Scientific, Wilmington, DE, USA). A total of 1µg of purified 
total RNA was used for cDNA synthesis using the iScriptcDNA Synthesis Kit (Bio-Rad, 
Hercules, CA, USA) according to the manufacturer’s protocols. The reaction was incubated 
at 25°C for 5 minutes, followed by 42°C for 30 minutes, and terminated at 85°C for 5 
minutes. After reverse transcription, the cDNA reaction mixture was diluted to a volume of 
50 µl with nuclease-free water and used as a template for qPCR analyses. Real-time PCR 
analyses were conducted using the Applied Biosystems 7300 Real-Time PCR System 
(Applied Biosystems, Foster City, CA, USA). Primers for qRT-PCR analyses (listed in 
Additional file 3) were designed using the Primer3 software [44] and synthesized by the 
Integrated DNA Technologies (Coralville, IA, USA). The relative quantity of transcripts in 
each sample was calculated using standard curves based on the relative quantity of 18S RNA 
transcript in 10-fold serial dilutions of that sample. 
Cloning 
DNA was isolated from SH-SY5Y cells using the DNeasy Blood and Tissue Kit (Qiagen) 
according to the manufacturer’s protocols. The promoter regions of RORA were then 
amplified by a PCR method tailored for long stretches of nucleotides using the GoTaq Long 
PCR Master Mix (Promega, Madison, WI, USA) and DNA primers tagged with SfiI 
restriction sites at the 5′ end (Integrated DNA Technologies) according to the manufacturer’s 
protocols. Primers for PCR cloning are listed in Additional file 3. Briefly, a total of 0.5 µg of 
purified human genomic DNA isolated from SH-SY5Y cells was combined with the GoTaq 
Long PCR Master Mix and 10 µM (final concentration) of each DNA primer. The thermal 
cycling condition was set as follows: 95°C for 2 minutes, 30 cycles of 92°C for 30 seconds 
and 65°C for 15 minutes, followed by 72°C for 10 minutes. PCR products were analyzed by 
gel electrophoresis using 1% agarose. The bands with expected sizes were excised from the 
gel and purified using the Wizard SV Gel and PCR Clean-Up System (Promega). 
Purified PCR products with different sizes were then separately inserted into pGEM-T Easy 
Vector (Promega) containing lacZ and ampicillin-resistant genes following the 
manufacturer’s instructions. The vector containing each PCR product was transformed into 
JM109 High-Efficiency Competent E.coli cells (Promega) by heat-shocking at exactly 42°C 
in a water bath for 50 seconds. Transformed bacteria were spread on duplicate Luria-Bertani 
LB agar plates containing 100 µg/ml ampicillin, 0.5 mM isopropyl-β-D-thio-galactoside 
(IPTG), and 80 µg/ml 5-bromo-4-chloro-indolyl-β-D-galactopyranoside (X-Gal), and 
incubated at 37°C overnight for blue-white screening. Well-isolated white colonies were 
selected and further cultured in LB medium supplemented with 125 µg/ml ampicillin at 37°C 
for 12 to 16 hours with shaking at 250 rpm. 
Plasmid DNA was purified from bacteria using the Wizard Plus SV Minipreps DNA 
Purification System (Promega) according to the manufacturer’s protocol. Presence of RORA 
promoter in the plasmid was validated by long PCR analysis using GoTaq Long PCR Master 
Mix (Promega), followed by gel electrophoresis. RORA promoter inserts were then released 
from the pGEM-T Easy plasmids using SfiI restriction enzyme and purified by gel 
electrophoresis. The luciferase vector pGL4.20[luc2/Puro] (Promega) containing firefly 
luciferase, puromycin-resistant, and ampicillin-resistant genes was prepared by digestion with 
the SfiI restriction enzyme and dephosphorylation using TSAP Thermosensitive Alkaline 
Phosphatase (Promega) to prevent self-recircularization of the linearized vector during 
ligation. RORA promoter inserts were then ligated into the dephosphorylated luciferase vector 
using LigaFast Rapid DNA Ligation System (Promega) and transformed into the JM109 
High-Efficiency Competent E.coli cells. Transformed bacteria were cultured on LB agar plate 
containing 125 µg/ml ampicillin. Colonies of bacteria were harvested and further cultured in 
LB medium containing 125 µg/ml ampicillin overnight. Luciferase plasmids containing the 
RORA promoter regions were then purified from the transformed bacteria using Wizard Plus 
SV Minipreps DNA Purification System (Promega). Presence of RORA promoter insert was 
confirmed by long PCR analysis. 
Dual-luciferase reporter assays 
The pGL4.20[luc2/Puro] vector containing a specific RORA promoter region was mixed with 
the pGL4.74[hRluc/TK] vector containing Renilla reniformis luciferase gene with a ratio of 
50:1 in phenol red-free Opti-MEM I reduced-serum medium (Invitrogen). The FuGENE HD 
Transfection Reagent (Promega) was then added to the medium containing the vectors to 
obtain a ratio of 3:1 (that is, 3 µl transfection agent for 1 µg DNA). The mixture was added to 
a 96-well plate containing SH-SY5Y cells approximately 2 × 104 cells/well) and incubated at 
37°C, 5% CO2, for 48 hours. The transfected cells were treated with 10 nM DHT, 10 nM E2, 
or ethanol control for 2 hours, then dual-luciferase reporter assays (duplicates) were 
performed using the Dual-Luciferase Reporter Assay System (Promega) according to the 
manufacturer’s protocol. Briefly, lysis buffer was added to the 96-well plates containing 
hormone-treated transfected cells and complete lysis of cells was assessed under an inverted 
microscope. Cell lysates were collected and transferred to Cellstar 96-well plate (BioExpress, 
Kaysville, UT, USA). A Veritas Microplate Luminometer (Turner Biosystems, Sunnyvale, 
CA, USA) was used for detection of firefly and Renilla luminescence as well as for 
measurement of both firefly and Renilla luciferase activity signals. Firefly luciferase 
luminescence in each well was normalized by Renilla luciferase luminescence in the same 
well. 
Prediction of transcription factor binding elements 
Putative binding sites of AR and ERα in the human RORA1 promoter region and putative 
binding sites of RORA in the promoter regions of CYP19A1 were predicted using PROMO 
3.0 [45,46], JASPAR [47], and SABiosciences EpiTect ChIP Search Portal (SABiosciences, 
Valencia, CA, USA) programs. For each gene, a total of three to four predicted transcription 
factor binding sites (listed in Additional file 4) were selected for chromatin 
immunoprecipitation analyses. 
Chromatin immunoprecipitation 
Chromatin was isolated from SH-SY5Y cells and sheared using the ChIP-IT Express 
Enzymatic Kit (Active Motif, Carlsbad, CA, USA) according to the manufacturer’s 
instructions. Briefly, confluent SH-SY5Y cells (approximately 1.5 × 107 cells in a T-175 
flask) were fixed with 10% formaldehyde for exactly 5 minutes and the fixation reaction was 
stopped by adding 10% glycine. The cells were washed with 10 ml ice-cold PBS for 5 
seconds, then 6 ml ice-cold PBS supplemented with 0.5 mM (final concentration) 
phenylmethylsulfonyl fluoride (PMSF) supplied in the kit was added to the culture flask to 
wash and chill the cells. The crosslinked cells were transferred from the flask to a pre-chilled 
centrifuge tube by scraping gently with a cell scraper. Crosslinked cells were homogenized 
by douncing 40 to 50 times on ice using a dounce homogenizer with a tight pestle to release 
the nucleus. Optimal cell lysis was assessed under a phase contrast microscope using a 
hemacytometer. The cell lysate was transferred to a 1.7 ml microcentrifuge tube and 
centrifuged for 10 minutes at 5,000 rpm (2,400 RCF) in a 4°C microcentrifuge to pellet 
nuclei. Chromatin was then isolated from the nuclear pellets and sheared into 150 to 1,000 bp 
fragments by incubating with 10 U/ml (final concentration) Enzymatic Shearing Cocktail 
(Active Motif) at 37°C for exactly 10 minutes. The enzymatic shearing reaction was stopped 
by adding EDTA to a final concentration of 10 mM EDTA and chilling the reaction tube on 
ice for 10 minutes. To assess shearing efficiency and determine DNA concentration in the 
sheared chromatin, a 50 µl aliquot of each sheared chromatin sample was reverse-crosslinked 
by mixing with 150 µl nuclease-free water and 10 µl 5M NaCl. The reaction was incubated at 
65°C in a water bath overnight. After incubation, 1 µl RNaseA (10 µg/µl) was added to each 
tube and the reaction was incubated at 37°C for 15 minutes. The reaction was then mixed 
with 10 µl Proteinase K (0.5 µg/µl) and further incubated at 42°C for 1.5 hours. The reverse-
crosslinked DNA was isolated using standard phenol/chloroform extraction technique and 
purified using the Chromatin IP DNA Purification Kit (Active Motif). DNA concentration 
was measured using a NanoDrop 1000 spectrophotometer (Thermo Scientific, Wilmington, 
DE, USA). Optimal shearing was assessed by agarose gel electrophoresis. For chromatin 
immunoprecipitation reaction, the remaining enzymatically sheared, non-reverse-crosslinked 
chromatin was aliquoted into multiple tubes, each of which contained approximately 25 µg 
chromatin DNA. 
Each aliquot of chromatin was then used as input chromatin for sequential 
immunoprecipitation according to the manufacturer’s protocol for the Re-ChIP-IT Kit (Actif 
Motif). For each reaction, sheared chromatin (approximately 25 µg per reaction) was first 
immunoprecipitated by mixing with 1 µg of anti-AR, anti-ERα, anti-RORA, or IgG antibody 
and 25 µl Protein G Magnetic Beads (Active Motif). The reaction was then incubated on an 
end-to-end rotator overnight at 4°C. After incubation, the immunoprecipitated chromatin was 
eluted from the magnetic beads using the Re-ChIP-IT Elution Buffer (Active Motif) and 
desalted using the Active Motif Desalting Columns to remove the first antibody on the 
chromatin. Then, 1 µg of the second antibody (anti-NCOA1, anti-NCOA5, anti-SUMO1, 
anti-FHL2, or IgG antibody) and 25 µl of the LSV Protein G Magnetic Beads (Active Motif) 
were added to the desalted chromatin (approximately 90 µl) and incubated on an end-to-end 
rotator overnight at 4°C to re-immunoprecipitate the chromatin. To validate that successful 
re-immunoprecipitation was caused by the second antibody and not by carried over first 
antibody, a re-immunoprecipitation reaction without the second antibody (that is, no-second-
antibody control) was also performed in parallel and included in subsequent qPCR analysis. 
After incubation, DNA from re-immunoprecipitated chromatin was isolated and purified 
using the ChIP DNA Purification Kit (Active Motif). The list of antibodies for sequential 
ChIP is shown in Additional file 1. 
Real-time, quantitative PCR analysis of immunoprecipitated DNA 
Real-Time qPCR analysis was conducted using Applied Biosystems 7300 Real-Time PCR 
System (Applied Biosystems) to determine the enrichment of each AR/ERα/RORA binding 
element in immunoprecipitated or sequentially immunoprecipitated DNA. Primers for qPCR 
analysis were designed using Primer3 software [44] and synthesized by Integrated DNA 
Technologies (IDT). Input DNA was diluted into five 10-fold serial dilutions and included in 
the qPCR analysis. Relative enrichment values of AR/ERα/RORA binding elements in each 
sequentially immunoprecipitated chromatin were calculated using standard curves obtained 
from the enrichment of respective AR/ERα/RORA binding elements in the 10-fold serial 
dilutions of input DNA. The list of primers is shown in Additional file 3. 
Co-immunoprecipitation analysis 
The SH-SY5Y cells were cultured in complete growth medium until the confluency was 
approximately 70 to 80% and hormone treatment was conducted as mentioned above. Co-
immunoprecipitation (co-IP) assays were then conducted using Pierce Crosslink Magnetic 
IP/Co-IP Kit (Thermo Scientific) according to the manufacturer’s protocol, using antibodies 
against four coregulator proteins that were found to be differentially expressed in LCL from 
individuals with ASD relative to that of unaffected controls ([15]; see Additional file 5). 
Briefly, the medium was removed from the flask containing cells. Then, cells were washed 
with ice-cold PBS containing phosphatase and deacetylase inhibitors and whole-cell lysis 
buffer was added directly into the flask. Protein A/G magnetic beads for immunoprecipitation 
were treated with anti-NCOA1, anti-NCOA5, anti-SUMO1, anti-FHL2, or nonspecific IgG 
antibody, and the antibody-bound magnetic beads were crosslinked with 20 µM 
disuccinimidyl suberate. The list of antibodies used is shown in Additional file 1. The 
crosslinked magnetic beads were mixed with SH-SY5Y whole-cell extract and incubated 
overnight at 4°C. The magnetic beads were then collected and protein complexes bound to 
the beads were eluted. Eluted immunoprecipitated proteins were used for subsequent western 
blot analysis as described below to determine the enrichment of AR, ERα, or RORA protein. 
BCA assays 
Protein concentration was determined by BCA assays using Pierce BCA Protein Assay Kit 
(Thermo Scientific) according to the manufacturer’s directions for microplate assays. Briefly, 
the sample was mixed with BCA reagent containing bicinchoninic acid (BCA) and cupric 
sulfate and incubated at 37°C for 30 minutes. To determine protein concentration in an 
unknown sample, serial dilutions of bovine serum albumin (25 to 2,000 µg/ml) were included 
in the analysis and used for creating a standard curve. The absorbance of each sample was 
measured at 562 nm using a Synergy HT Multi-Mode microplate reader (BioTek, Winooski, 
VT, USA). The protein concentration in each unknown sample was calculated using standard 
curves obtained from absorbance values of the serial dilutions of albumin standards. 
Western blot analysis 
A total of 30 µg of protein was mixed with 5X Thermo Scientific Lane Marker Non-
Reducing Sample Buffer (Thermo Scientific) containing 0.3 M Tris–HCl, 5% SDS, 50% 
glycerol, and pink tracking dye. The sample was boiled for 5 minutes and loaded onto a Mini-
PROTEAN TGX precast polyacrylamide gel (Bio-Rad, Hercules, CA, USA). Electrophoresis 
was conducted at 200 V using 1X Tris-glycine buffer containing 25 mM Tris base, 190 mM 
glycine, and 0.1% SDS, as a running buffer. Proteins on the gel were then transferred to 
polyvinylidene fluoride (PVDF) membrane and blocking was performed for 1 hour at 4°C 
using 5% (w/v) non-fat dry milk (Bio-Rad) in Tris-buffered saline and Tween 20 (TBST) 
buffer containing 2.42 g Trizma-HCl, 8 g NaCl, and 1X Tween 20. Protein detection was 
conducted by incubating the PVDF membrane with anti-AR, anti-ERα, anti-RORA, or anti-
RORA1 antibody (1:200 in 1% milk/TBST) at 4°C overnight. The membrane was washed 
and treated with donkey secondary antibody conjugated with horseradish peroxidase (HRP; 
Santa Cruz Biotechnology; 1:2,500) for 1 hour at room temperature. Protein visualization was 
performed using a chemiluminescence method by incubating the membrane in 
chemiluminescence substrates (PerkinElmer, Waltham, MA, USA). Protein signals on the 
membrane were detected using a ChemiDoc XRS+ Imager (Bio-Rad). 
Statistical analyses 
The two-tailed Student t test was used to determine the statistical significance of differences 
in the means of two groups. A P value of less than 0.05 was considered statistically 
significant. For comparisons of the means of three or more groups, ANOVA followed by post 
hoc t tests were conducted using the StatPac (Pepin, WI, USA) statistics calculator. A P value 
of less than 0.05 was considered statistically significant. 
Results 
AR and ERα are required for sex hormone regulation of RORA 
We have recently demonstrated that AR and ERα are recruited to the RORA promoter region 
in the presence of DHT and E2, respectively [16]. However, androgens and estrogens are also 
capable of regulating their transcriptional targets through AR- and ERα-independent 
mechanisms. To determine whether DHT mediates its repressive effect on RORA expression 
through AR, we transfected the human neuronal cells SH-SY5Y with siRNA against AR 
(siAR) prior to treatment with DHT for 2 hours. RORA expression, measured by qRT-PCR 
analysis, was compared with that in mock-transfected cells treated with DHT or ethanol. 
Unlike the DHT-treated mock control cells, which exhibited a significant decrease in RORA 
expression, the expression of RORA in the siAR-transfected cells treated with DHT was not 
significantly changed in comparison with mock-transfected cells treated with ethanol (Figure 
1A), indicating that AR is required for DHT-mediated repression of RORA. 
Figure 1 siRNA-mediated knockdown of AR and ERα reveals direct role of hormone 
receptors in regulation of RORA expression by sex hormones. SH-SY5Y cells were 
transfected with siAR (A), siERα (B), or vehicle control (mock-transfected) for 24 hours, 
then treated with 1 nM DHT (A), 1 nM E2 (B), or ethanol for 2 hours. Quantitative RT-PCR 
analysis (n = 3) of the hormone-treated, transfected cells was conducted to determine RORA 
expression. Relative RORA quantity in each sample was calculated using a standard curve 
obtained from 18S expression levels in 10-fold serial dilutions of that sample. Error bars 
indicate SEM. Statistical significance of the differences between groups was determined by 
ANOVA (P <0.01 for each knockdown experiment) followed by post hoc t tests. *P <0.05. 
AR, androgen receptor; DHT, 4,5α-dihydrotestosterone; E2, 17β-estradiol; ERα, estrogen 
receptor alpha; SEM, standard error of the mean. 
To determine whether ERα is required for E2-mediated upregulation of RORA, we 
transfected the cells with siERα before treatment with E2 following the same protocol used 
for the aforementioned AR knockdown. Figure 1B shows that the increase in RORA 
expression in response to E2 was significantly attenuated (though not completely abolished) 
in the siERα-transfected cells in comparison with the mock-transfected cells, indicating that 
ERα is involved in the upregulation of RORA mediated by E2. These results led us to further 
investigate the molecular mechanisms involved in sex hormone regulation of RORA through 
AR and ERα. 
Androgen and estrogen require distal AR/ERα promoter binding elements to 
inversely modulate RORA 
AR and ERα are able to regulate transcription by binding directly to specific DNA elements 
in the promoter region of their target genes as well as by non-genomic mechanisms. The 
RORA promoter region contains multiple binding sites for AR and ER spanning a region as 
far as approximately 10 kb upstream of the transcription start site (TSS). In our previous 
study, we selected four ER binding sites (ERbs-I, -II, -III, and IV) and three AR binding sites 
(ARbs-I, -II, and -III) located within 10 kb upstream of the TSS of RORA for chromatin 
immunoprecipitation analysis of hormone receptor binding (Figure 2). We found that AR and 
ERα are recruited to some of these binding elements in the presence of DHT and E2, 
respectively [16]. However, it is still unclear which binding sites are involved in the DHT-
mediated downregulation and E2-mediated upregulation of RORA. We therefore constructed 
several firefly luciferase vectors containing different AR/ERα binding sites in the region 
upstream of the TSS and then conducted dual luciferase reporter assays of promoter activity 
in SH-SY5Y cells treated with DHT, E2, or ethanol, using the co-transfected Renilla 
luciferase vector as a negative control. The firefly luminescence signal in each reaction was 
normalized with the signal from Renilla luciferase in the same reaction to account for the 
variability between transfection experiments. 
Figure 2 Schematic diagram showing the upstream region of the RORA gene (edited 
from the UCSC Genome Browser). Potential AR and ER binding sites are labeled (ARbs, = 
AR potential binding site; ERbs, = ER potential binding site). AR, androgen receptor; ER, 
estrogen receptor. 
Interestingly, the firefly luciferase gene was oppositely regulated by DHT and E2 in the 
directions previously observed with endogenous RORA only when the gene was driven by the 
longest RORA promoter region (−10055 to −48) containing ARbs-I-III and ERbs-I-IV (Table 
1). Consistent with the findings from our previous study [16], DHT significantly suppressed 
RORA promoter-driven luciferase activity (P value <0.05), whereas E2 enhanced it by over 
2.5 fold (P value <0.05). When ERbs-I was deleted, the enhancing effect of E2 on RORA 
promoter activity was completely diminished and, instead, the luciferase activity was 
significantly suppressed by E2. This finding indicates that the ERbs-I is critical for the 
upregulation of RORA transcription by E2. Without ERbs-I, E2 has a negative effect on 
RORA promoter activity. 
Table 1 Fold-change in RORA promoter-driven luciferase activity in response to DHT 
or E2 
Region of RORA promoter fused 
to luciferase (bp from TSS) 
AR and ER binding sites 
in promoter region 
Fold-change*with 
DHT (P value¥) 
Fold-change*with E2 
(P value¥) 
−48 to −10055 ARbs-I-III; ERbs-I-IV 0.78 (0.020) 2.29 (0.021) 
−48 to −6000 ARbs-I-III; ERbs-II-IV 0.81 (0.008) 0.71 (0.001) 
−48 to −2344 ARbs-II-III; ERbs-II-IV 1.22 (0.024) 0.86 (0.035) 
−48 to −1992 ARbs-III; ERbs-IV 0.83 (0.007) 0.74 (0.001) 
*Fold-change relative to vehicle treatment; ¥two-tailed t test. DHT, 4,5α-dihydrotestosterone; 
E2, 17β-estradiol; AR, androgen receptor; ERα, estrogen receptor alpha; ARbs, AR potential 
binding site; ERbs, ER potential binding site. 
SH-SY5Y cells were transfected with expression vectors containing different RORA promoter 
constructs fused to the firefly luciferase gene together with a second expression vector 
containing the Renilla luciferase gene, at a ratio of 50:1. After a 2-hour treatment with the 
indicated hormone or vehicle (ethanol), firefly luciferase luminescence was determined for 
each sample and normalized by Renilla luminescence in the same sample. T tests were 
performed to determine the significance of the differences between hormone-treated and 
ethanol-treated samples. There were no significant differences in firefly luciferase activity 
between hormone-treated and vehicle-treated samples when the cells were transfected with 
the empty vector (that is, no RORA promoter). 
In the presence of all AR binding sites in the RORA promoter region, the luciferase activity 
was significantly suppressed by DHT (Table 1). When ARbs-I was deleted, DHT 
significantly enhanced, rather than suppressed, promoter activity (P value <0.01). However, 
when both ARbs-I and -II were deleted, the suppressive effect of DHT on RORA promoter-
driven luciferase activity was restored. This finding indicates that DHT can induce 
suppression of RORA promoter activity through ARbs-I and ARbs-III, but enhancement of 
the promoter activity through ARbs-II. These data indicate that the promoter region between 
−2344 and −10055 upstream of the RORA TSS which contains both ARbs-I and ERbs-I is 
required for DHT-mediated downregulation and E2-mediated upregulation of RORA. 
Identification of AR and ERα coregulators involved in sex hormone 
regulation of RORA 
Hormone receptors such as AR and ERα must associate with coregulator proteins to regulate 
expression of their transcriptional targets. Although a number of AR and ERα coregulator 
proteins have been identified elsewhere, it is unknown which coregulators are involved in sex 
hormone regulation of RORA, particularly in the context of neuronal cells. We thus sought to 
identify coregulator proteins that interact specifically with AR and ERα at ARbs-I and ERbs-
I, respectively. 
As mentioned earlier, we found a number of nuclear receptor coregulators differentially 
expressed in LCL derived from individuals with ASD relative to sex-matched typically 
developing individuals [15]. These coregulators included NCOA1, NCOA5, SUMO1, and 
FHL2, with known associations with AR and ERα. To determine whether these coregulators 
interact with AR in human neuronal cells, co-immunoprecipitation analyses were performed 
using whole-cell lysates of DHT-treated SH-SY5Y cells and anti-NCOA1, anti-NCOA5, anti-
SUMO1, anti-FHL2, or nonspecific IgG antibody. Western blot analysis showed that AR was 
clearly enriched in protein samples immunoprecipitated with antibodies to NCOA1, NCOA5, 
and SUMO1, with only marginal enrichment with antibody to FHL2, in comparison with AR 
in the IgG-immunoprecipitated sample (Figure 3A), indicating that AR is capable of 
interacting with these coregulators in the human neuronal cell line. Similar co-
immunoprecipitation analyses using cells treated with E2 showed an increase in the 
enrichment of ERα protein in protein samples co-immunoprecipitated with NCOA5 and, to a 
lesser extent, with FHL2 (Figure 3B), indicating that ERα interacts with these two 
coregulators in the human neuronal cell line SH-SY5Y. 
Figure 3 Co-immunoprecipitation analysis of AR/ERα coregulators. Whole-cell lysates 
of SH-SY5Y cells treated with 1nM DHT (A) or 1nM E2 (B) for 2 hours were 
immunoprecipitated with anti-NCOA1, anti-NCOA5, anti-SUMO1, anti-FHL2, or IgG 
antibody. Western blot analyses were performed to determine the enrichment of AR (A) and 
ERα (B) in the immunoprecipitated complexes. AR, androgen receptor; DHT, 4,5α-
dihydrotestosterone; E2, 17β-estradiol; ERα, estrogen receptor alpha. 
To further determine whether these coregulators are involved in AR-mediated regulation of 
RORA in human neuronal cells, sequential chromatin immunoprecipitation (ChIP-reChIP) 
analysis of SH-SY5Y cell lysates was conducted using anti-AR antibody, followed by each of 
the anti-coregulator antibodies in separate reactions. The enrichment of AR binding sites in 
the RORA promoter region was then determined by qPCR analysis of the reChIP samples. An 
increase in the average enrichment of ARbs-I was observed in the chromatin sample 
sequentially immunoprecipitated with antibody to AR, followed by antibody to SUMO1 
(Figure 4A). Because there was a high degree of variability in the enrichment of ARbs-I in 
SUMO1 re-immunoprecipitated chromatin, which is probably due to low expression of AR in 
the SH-SY5Y cells, we conducted PCR using DNA resulting from the sequential 
immunoprecipitation and primers designed to amplify ARbs-I, and then visualized the PCR 
product by gel electrophoresis. As shown in Figure 4B, ARbs-I was enriched in the product 
that resulted from the sequential ChIP with AR and SUMO1 antibodies, in comparison with 
that resulting from pull down with nonspecific IgG. This finding confirms that AR interacts 
with SUMO1 at the AR binding element ARbs-I in the RORA promoter region. 
Figure 4 ChIP-reChIP analyses identify coregulators that associate with AR/ERα on the 
RORA promoter. (A) SH-SY5Y cells were treated with 1 nM DHT and whole-cell lysates 
were prepared and immunoprecipitated with anti-AR or IgG antibody. The 
immunoprecipitated chromatin-antibody complex was then dissociated and washed to remove 
the antibody. The immunoprecipitated chromatin was then re-immunoprecipitated using anti-
NCOA1, anti-NCOA5, anti-SUMO1, anti-FHL2, nonspecific IgG antibody, or no-second-
antibody negative control. The enrichment of AR binding sites in the RORA promoter region 
in each re-ChIP sample was then determined using qPCR analysis (n = 3) and normalized 
with reference to the no-second-antibody control. (B) Gel electrophoresis analysis of PCR 
products using input chromatin, chromatin immunoprecipitated with anti-AR followed by 
anti-SUMO1 antibody, or IgG followed by IgG, as templates. PCR primers were designed to 
specifically amplify ARbs-I. (C) ChIP-reChIP analysis of coregulators associated with ERα 
binding sites in RORA promoter was conducted in the same manner as for AR binding sites 
using SH-SY5Y cells treated with 1nM E2. Error bar indicates SEM. **P <0.01, *P <0.05. 
AR, androgen receptor; ChIP-reChIP, sequential chromatin immunoprecipitation; DHT, 4,5α-
dihydrotestosterone; E2, 17β-estradiol; ERα, estrogen receptor alpha; SEM, standard error of 
the mean. 
ChIP-reChIP analysis of coregulators associated with ERα at its receptor binding sites in the 
RORA promoter was conducted in the same manner as for AR binding sites using SH-SY5Y 
cells treated with E2. Figure 4C shows a significant increase in the enrichment of ERbs-I in 
the reChIP reaction with anti-NCOA5, while ERbs-IV was significantly enriched when 
antibody against FHL2 was used for the second ChIP. This finding indicates that ERα 
interacts with NCOA5 at ERbs-I and FHL2 at ERbs-IV on the RORA promoter. 
Regulation of RORA by sex hormones is mediated by SUMO1 and NCOA5 
To further confirm that SUMO1 is required for DHT-mediated regulation of RORA, SUMO1 
expression in SH-SY5Y cells was suppressed using siSUMO1 and the transfected cells were 
then treated with 1 nM DHT. Using qRT-PCR analysis to measure RORA expression in 
siRNA-transfected cells, we found that the suppressive effect of DHT on RORA expression 
was completely abolished in cells transfected with siSUMO1 (Figure 5A), indicating that 
SUMO1 is required for DHT-mediated suppression of RORA. Similarly, we conducted 
siNCOA5 transfection and E2 treatment to confirm that NCOA5 is involved in E2-mediated 
regulation of RORA. The enhancing effect of E2 on RORA expression was significantly 
reduced (but not completely) in siNCOA5-transfected cells (Figure 5B), indicating that 
NCOA5 is involved in E2-mediated upregulation of RORA. 
Figure 5 siRNA-mediated knockdown of SUMO1 and NCOA5 show functional 
involvement of these coregulators in the regulation of RORA expression by AR and 
ERα, respectively. (A) SH-SY5Y cells were transfected with siSUMO1 or vehicle control 
for 24 hours and treated with 1nM DHT or ethanol for 2 hours. RORA expression was then 
measured by qRT-PCR analysis (n = 3). Relative RORA quantity in each sample was 
calculated using a standard curve obtained from 18S expression levels in 10-fold serial 
dilutions of that sample. (B) NCOA5 knockdown was performed in the same manner as for 
SUMO1 and cells were treated with 1 nM E2. Error bars indicate SEM. Statistical 
significance of the differences between groups was determined by ANOVA (P <0.001 for 
each knockdown experiment) followed by post hoc t tests. **P <0.01. AR, androgen 
receptor; DHT, 4,5α-dihydrotestosterone; E2, 17β-estradiol; ERα, estrogen receptor alpha; 
SEM, standard error of the mean 
Identification of RORA coregulators involved in regulation of CYP19A1 
Inasmuch as RORA is also known to interact with coregulators to regulate the transcription of 
target genes, we therefore sought to determine whether the coregulators that we selected for 
this study are also involved in RORA-mediated regulation of gene transcription in human 
neuronal cells. We have recently demonstrated that RORA can potentially regulate the 
transcription of more than 2500 genes enriched for neurological functions implicated in ASD, 
and further validated several ASD-relevant genes, including A2BP1, CYP19A1, HSD17B10, 
ITPR1, NLGN1, and NTRK2, as transcriptional targets of RORA [38]. In this study, we 
investigated coregulator involvement in RORA-mediated regulation of CYP19A1 because we 
have previously demonstrated that RORA protein is recruited to the promoter region of 
CYP19A1 [16], RORA overexpression causes an increase in CYP19A1 expression [16], and 
the expression of CYP19A1 (aromatase) protein is significantly reduced in brain tissues from 
ASD individuals as well as highly correlated with that of RORA [16]. 
We first determined whether RORA interacts with the coregulators NCOA1, NCOA5, 
SUMO1, and FHL2 in SH-SY5Y cells by co-immunoprecipitation followed by western blot 
analysis of RORA protein. Figure 6 shows that RORA is enriched in protein samples 
immunoprecipitated with NCOA1 and NCOA5, indicating that RORA interacts with these 
coregulators in the human neuronal cell line SH-SY5Y. To determine whether these 
coregulators are also involved in regulation of the CYP19A1 gene, we conducted sequential 
chromatin immunoprecipitation using anti-RORA or IgG antibody, followed by reChIP using 
anti-NCOA1, anti-NCOA5, anti-SUMO1, anti-FHL2, or IgG antibody. The enrichment of 
each potential binding site for RORA (RORAbs) on the CYP19A1 promoter (Figure 7A) in 
the re-immunoprecipitated chromatin was determined by qPCR analysis. Figure 7B shows an 
increase in the average enrichment of RORAbs-I in the promoter region of CYP19A1 when 
chromatin was sequentially immunoprecipitated by anti-RORA, followed by anti-NCOA5 
antibody , indicating that RORA interacts with NCOA5 at this RORA binding site in the 
promoter region of CYP19A1. 
Figure 6 Co-immunoprecipitation analysis of RORA coregulators. Whole-cell lysates of 
SH-SY5Y cells were prepared and immunoprecipitated with anti-NCOA1, anti-NCOA5, anti-
SUMO1, anti-FHL2, or IgG antibody. Western blot analysis was used to determine the 
enrichment of RORA protein in the immunoprecipitates. 
Figure 7 ChIP-reChIP analysis of RORA coregulators binding to the CYP19A1 
promoter region. (A) Schematic diagram showing the upstream region of the CYP19A1 
gene (edited from the UCSC Genome Browser). Potential RORA binding sites are labeled 
(RORAbs = RORA potential binding site). (B) Sequential chromatin immunoprecipitation 
(ChIP-reChIP) followed by qPCR analysis was conducted to determine whether NCOA1, 
NCOA5, SUMO1, or FHL2 interact with RORA in the CYP19A1 promoter region. RORAbs-
II and III are located adjacent to each other and cannot be analyzed separately by qPCR 
analysis, and are thus shown as RORAbs-II/III. Chromatin was isolated from SH-SY5Y cells 
and first immunoprecipitated with anti-RORA. The RORA-immunoprecipitated chromatin 
was washed to remove anti-RORA, then free chromatin was re-immunoprecipitated with anti-
NCOA1, anti-NCOA5, anti-SUMO1, anti-FHL2, or nonspecific IgG, and a no-second-
antibody control was also included. The enrichment of RORA binding sites in the CYP19A1 
promoter region in each re-ChIP sample was then determined using qPCR analysis (n = 3) 
and normalized with reference to the no-second-antibody control. Error bars indicate SEM. 
#Undetectable. ChIP-reChIP, sequential chromatin immunoprecipitation; SEM, standard 
error of the mean. 
Discussion 
We have previously shown that male and female hormones inversely regulate the expression 
of RORA, a nuclear receptor deficient in the brain and lymphoblastoid cell lines derived from 
a subset of individuals with ASD [12,15], with DHT reducing RORA expression and E2 
increasing it [16]. Because the reduction of RORA protein in brain tissues from individuals 
with ASD was highly correlated with reduction of aromatase (CYP19A1) protein which 
enzymatically converts testosterone to estradiol, these results suggested a molecular 
explanation for the observed increase in testosterone that has been associated with autistic 
traits [6-8,48-50]. On the other hand, we hypothesized that females might be more protected 
against RORA deficiency due to higher levels of E2 that stimulate RORA expression, thus 
reducing risk for ASD relative to males. However, the mechanisms for the suppression of 
RORA expression by DHT and the upregulation by E2 were unknown. This study was 
undertaken to investigate the mechanisms through which the sex hormones regulate RORA 
and, in particular, to identify the molecular determinants for the opposite regulation by male 
and female hormones. Moreover, having recently validated CYP19A1 as a transcriptional 
target of RORA [38], we further investigated the mechanism of CYP19A1 regulation by 
RORA. 
Involvement of AR and ER in the transcriptional regulation of RORA 
Because androgens and estrogens can mediate transcriptional changes without directly 
involving their respective hormone receptors, we first sought to determine whether or not AR 
and ER were directly involved in the regulation of RORA. The results presented here 
demonstrate the direct involvement of both hormone receptors in the transcriptional 
regulation of RORA, and furthermore identify specific hormone receptor binding sites within 
the extended 10 kb region upstream of the RORA TSS that participate in the up- or 
downregulation of RORA expression by the hormones acting upon a RORA-promoter-driven 
luciferase reporter construct. Interestingly, male and female hormones can exert both 
stimulatory and inhibitory effects on luciferase expression, depending on the presence of 
specific hormone receptor binding sites within the RORA promoter construct. Because 
hormone receptors are known to regulate their target genes in association with either 
coactivator or corepressor proteins [51,52], we then investigated coregulator involvement in 
AR- and ER-mediated regulation of RORA within the SH-SY5Y neuronal cell model, 
focusing on four coregulators that were found to be differentially expressed in the severely 
language-impaired subtype of ASD that was also deficient in RORA [15]. 
Identification of coregulator partners of AR and ER in the regulation of 
RORA 
Here we show by co-immunoprecipitation that several coregulators among the four examined 
can associate with AR and ERα in neuron-like SH-SY5Y cells. These included NCOA1, 
NCOA5, and SUMO1 associations with AR, and NCOA5 and FHL2 (to a lesser extent) 
associations with ERα. We then used ChIP-reChIP assays to interrogate associations of these 
four coregulator proteins with AR and ERα on specific hormone receptor binding sites on the 
RORA promoter. With respect to AR associations, SUMO1 showed the greatest enrichment 
relative to the no-second-ChIP-antibody control, and this enrichment was specific for ARbs-I. 
However, the enrichment was not statistically significant (P >0.05), most likely due to the 
low expression level of AR in these cells which were originally derived from a female. To 
increase the sensitivity of detecting enrichment of the ARbs-I in the ChIP-reChIP experiment 
involving SUMO1, DNA resulting from the sequential chromatin immunoprecipitation was 
amplified using primers designed specifically against ARbs-I, and gel electrophoresis of the 
PCR product was performed to confirm enrichment of ARbs-I in the sequential pull down 
using antibodies against AR and SUMO1 in comparison to that obtained with control IgG. 
Although SUMO1 is frequently found in covalent attachment to its targets, it is also 
considered a coregulator, according to the Nuclear Receptor Signaling Atlas 
(http://www.nursa.org) [53,54], that is often associated with transcriptional repression 
[55,56]. Indeed, SUMO1 associations with AR have been reported to modulate the 
transcriptional activity of AR [57]. In contrast to coregulator interactions with AR on the 
RORA promoter, ERα was found to significantly associate with NCOA5, a reported 
coactivator of ERα [58], at ERbs-I, while FHL2 was found to significantly associate with 
ERα at ERbs-IV. Interestingly, unlike other coregulators, NCOA5 does not require the 
ligand-dependent activation function-2 (AF2) domain of the target nuclear receptors for 
interaction, and can form complexes with both ERα and ERβ in the absence of ligand. On the 
other hand, FHL2 can exhibit dual coregulatory functions, acting as a corepressor of ERα and 
ERβ [59] and a coactivator of AR [60]. The differential associations of these two coregulators 
at different ER binding sites on the RORA promoter are interesting in light of the luciferase 
assays that revealed that the enhancing effect of E2 was manifested only when ERbs-I was 
present (on the 10kb promoter construct). In the absence of ERbs-I and NCOA5 binding to 
the RORA promoter, E2 had a repressive effect on RORA expression, possibly due to the 
binding of the ER corepressor FHL2 on the most proximal ER binding site, ERbs-IV. 
To determine the functional role of SUMO1 in the repression of RORA by DHT, we used 
siRNA against SUMO1 to reduce its expression in SH-SY5Y cells, and then monitored 
RORA expression in the presence and absence of DHT. The suppression of RORA expression 
by DHT treatment was completely abolished in the presence of siSUMO1, but not in the 
mock-treated control. Similarly, we monitored E2-mediated enhancement of RORA 
expression in siNCOA5-treated and mock-treated cells and found that siNCOA5 significantly 
reduced the upregulation of RORA expression by E2, but not completely, most likely due to 
incomplete knockdown of NCOA5 by siNCOA5 (as shown in Additional file 5). 
Alternatively, other untested coregulators may be involved in the E2-induced increase in 
RORA expression. Collectively, these results suggest that the regulation of RORA by 
androgen and estrogen is complex and dependent not only on the binding of the respective 
hormone receptors to specific hormone receptor binding sites on the RORA promoter, but also 
on the recruitment of specific coregulators to the hormone receptors. 
Identification of a coregulator in RORA-mediated regulation of CYP19A1 
Inasmuch as we have demonstrated that RORA is a nuclear hormone receptor that 
transcriptionally regulates CYP19A1 [38], we were interested in identifying coregulators that 
associate with RORA on the CYP19A1 promoter. Co-immunoprecipitation analyses using 
antibody against each of the four coregulators followed by western blot analyses for presence 
of RORA in the immunoprecipitates demonstrated that both NCOA1 and NCOA5 are capable 
of associating with RORA in SH-SY5Y cells, while SUMO1 and FHL2 do not. However, 
ChIP-reChIP analyses performed with anti-RORA antibody followed, in separate 
immunoprecipitations, by antibodies against each of the four coregulators showed that only 
NCOA5 could interact with RORA on the CYP19A1 promoter, and that the promoter binding 
involved only the more distal RORAbs-I. These studies suggest that NCOA5 can serve as a 
coregulator of both RORA and ERα within neuronal cells. This coincidence is interesting 
inasmuch as RORA and ER share the same consensus binding sites on DNA, AGGTCA, 
suggesting the overlap of at least some of their transcriptional targets. As suggested earlier, 
the existence of shared gene targets (including RORA) may in part compensate for RORA 
deficiency in females who, with higher levels of estrogen, exhibit lower susceptibility to 
ASD. 
Relevance of these findings to the sex bias in ASD 
Figure 8 presents a working model that integrates the results of these studies with those of our 
earlier studies that demonstrated the opposite regulation of RORA by male and female 
hormones and the regulation of CYP19A1 by RORA [16,38]. In this model, a reduction in 
RORA expression, which may be induced by increased methylation, which we have 
demonstrated previously in cell lines from individuals with ASD [12] is expected to lead to a 
decrease in CYP19A1 (aromatase), which, in turn, would result in the accumulation of its 
substrate testosterone. The highly active metabolite of testosterone, DHT, can then further 
suppress RORA expression, exacerbating RORA deficiency. Here, we show that the 
corepressor SUMO1 collaborates with AR in mediating the downregulation of RORA. Thus, 
an increase in SUMO1 expression, which we have detected in LCL from individuals with 
ASD relative to typical controls [15], may reinforce the androgen-mediated downregulation 
of RORA. Conversely, the model predicts that estradiol, the product of the aromatase 
reaction, is expected to decrease with the reduced expression of CYP19A1, and lower E2 
would therefore dampen RORA expression. This study shows that NCOA5 is a strong 
coactivator of ERα at the ERbs-I on the RORA promoter. Interestingly, the expression of 
NCOA5 is the most reduced among the differentially expressed coregulators in LCL derived 
from individuals with ASD [15]. Our study suggests that a reduction in this coactivator would 
further dampen RORA transcription via ER. The net outcome of the molecular changes and 
associations that we have identified in several studies regarding the hormonal regulation of 
RORA (and its transcriptional target, CYP19A1), their respective nuclear receptors and 
associated coregulators suggests that the aberrant expression of any of the genes in this 
interacting network in the directions that have been observed in our studies on cells and 
tissues from individuals with ASD can lead to increased testosterone, which has been linked 
to increased autistic traits [7,8,50]. Furthermore, our studies provide a plausible explanation 
for lower female susceptibility to ASD due to the positive effects of estrogen on RORA 
expression, which offers a buffer against conditions leading to RORA deficiency. 
Figure 8 A model for the opposite effects of male and female hormones on RORA 
expression. The schematic illustrates a mechanism through which the observed reduction in 
RORA in the autistic brain may lead to increased testosterone levels through downregulation 
of aromatase. Our model suggests that AR, in association with SUMO1 functioning as a 
corepressor, is directly involved in the suppression of RORA expression by testosterone, 
whereas ERα association with the coactivator NCOA5 is involved in the upregulation of 
RORA expression by estradiol. RORA, in turn, positively regulates expression of aromatase, 
probably by interacting with NCOA5. AR, androgen receptor; ERα, estrogen receptor alpha. 
Implications of coregulator involvement in the polygenicity of ASD 
This is the first study to demonstrate the involvement of coregulators in the hormonal 
regulation of a functionally relevant autism candidate gene, RORA, whose deficiency can 
impact multiple processes that are known to be disrupted or impaired in ASD, such as 
synaptogenesis, axon guidance, dendritic extension, neurotransmission, circadian regulation, 
and higher level functions, such as learning and speech [38]. Because coregulators interact in 
combinatorial fashion with different nuclear hormone receptors to modulate gene expression, 
often in response to endogenous as well as exogenous agents, coregulators have been 
proposed to be ‘key integrators of environmental signals’ and are thus likely contributors to 
the polygenic nature of complex diseases [61]. This study shows that the response of RORA 
to androgens and estrogens depends on both the availability of specific AR and ER binding 
sites on the RORA promoter as well as the recruitment of specific coregulators to the 
respective hormone receptors on the promoter. Coregulator involvement in gene 
dysregulation in ASD thus represents a new paradigm in the investigation of ASD, which are 
clearly complex polygenic disorders with many genes already implicated by large-scale 
genetics, gene expression, and epigenetic studies. 
Study limitations and future directions 
To gain additional insight into the molecular mechanisms involved in the regulation of RORA 
by sex hormones, we investigated the biochemical associations and functional involvement of 
hormone receptors and coregulator proteins in DHT- and E2-mediated down- and 
upregulation of RORA, respectively. However, we limited our study to selected coregulators 
that were differentially expressed in our previous expression profiling study of LCL from 
individuals with ASD rather than examine all possible coregulator interactions, as has been 
recently accomplished by proteomic analysis of coregulators of ERα which was targeted 
against a synthetic DNA template containing four tandem estrogen response elements fused 
to the adenovirus E4 gene promoter [62]. This comprehensive analysis of coregulator 
associations with ERα in nuclear extracts of MCF7 and HeLa cells revealed as many as 17 
coregulators that associated with the hormone receptor on the DNA template. Interestingly, 
this study also revealed that the associations could rapidly change in response to 
phosphorylation of the ERα-coregulator complexes, revealing the dynamic nature of 
coregulator binding to such complexes. Thus, our study provides only a restricted analysis of 
the possible coregulator associations with ERα and AR that can modulate RORA expression 
in response to sex hormones, and we cannot rule out the involvement of other coregulators 
not studied here. Furthermore, inasmuch as coregulator recruitment is known to be tissue 
specific [63], it will be of interest to investigate coregulator-hormone receptor complexes in 
the brain of individuals with ASD vs. that of typical individuals. 
Another limitation is that this study focuses only on ERα, while both ERα and ERβ are 
known to be ubiquitously expressed in the human brain throughout life. However, there is 
evidence that ERα may be more important in biological functions associated with autism, 
including early cortical development processes [64], regulation of transcriptional targets in 
the cortex [64,65], neuroprotection against cytotoxicity [66] and ischemia [67], and social 
discrimination [68]. Nevertheless, the mechanisms through which ERβ may be involved in 
regulation of RORA deserve further study since ERβ is also known to be highly expressed in 
cortex, amygdala, and cerebellum, where AR is also highly expressed [69]. Moreover, ERβ 
may be more important for development of future therapies addressing RORA deficiency 
because ERβ is known to have little or no expression in the breast or uterus. Thus, selective 
activation of ERβ may provide the beneficial effects of ER signaling in the brain without 
undesired effects in reproductive organs. 
Conclusions 
In summary, we show that AR and ERα are respectively involved in the suppression and 
enhancement of RORA expression by male and female hormones in a neuronal cell model, 
and that the corepressor SUMO1 is needed for AR-mediated suppression, while the 
coactivator NCOA5 is involved in the ER-mediated upregulation of RORA. We further 
demonstrate that NCOA5 can interact with RORA on the promoter of CYP19A1, revealing 
another similarity in gene regulatory mechanisms between RORA and ER which share the 
same DNA consensus binding sites. Finally, we show for the first time, the involvement of 
coregulators, when aberrantly expressed, as potential contributors to the polygenic nature of 
gene dysregulation in ASD. 
Abbreviations 
A2BP1, ataxin 2 binding protein 1 (also known as RBFOX1); AR, androgen receptor; ASD, 
autism spectrum disorder; BCA, bicinchoninic acid; ChIP, chromatin immunoprecipitation; 
ChIP-reChIP, sequential chromatin immunoprecipitation; Co-IP, co-immunoprecipitation; 
CYP19A1, cytochrome P450 family 19 subfamily A polypeptide 1; DHT, 4,5α-
dihydrotestosterone; (D)MEM, Dulbecco’s modified Eagle’s medium; E2, 17β-estradiol; 
EDTA, ethylenediaminetetraacetic acid; ERα, estrogen receptor alpha; ERβ, estrogen 
receptor beta; FHL2, four and a half LIM domains 2; HRP, horseradish peroxidase; 
HSD17B10, hydroxysteroid (17-beta) dehydrogenase 10; IPTG, isopropyl-β-D-thio-
galactoside; ITPR1, inositol 1,4,5-trisphosphate receptor type 1; LB, Luria-Bertani medium; 
LCL, lymphoblastoid cell line; NCOA1, nuclear receptor coactivator 1; NCOA5, nuclear 
receptor coactivator 5; NLGN1, neuroligin 1; NTRK2, neurotrophic tyrosine kinase receptor 
type 2; PBS, phosphate-buffered saline; PMSF, phenylmethylsulfonyl fluoride; PVDF, 
polyvinylidene fluoride; qRT-PCR, quantitative reverse transcriptase polymerase chain 
reaction; qPCR, quantitative polymerase chain reaction; RORA, retinoic acid receptor-related 
orphan receptor alpha; SEM, standard error of the mean; SDS, sodium dodecyl sulfate; SH-
SY5Y, human neuroblastoma cell line; siRNA, silencing RNA; SUMO1 SMT3, suppressor 
of mif two 3 homolog 1; TBST, Tris-buffered saline and Tween 20; TSAP, thermosensitive 
alkaline phosphatase; TSS, transcription start site; X-Gal, 5-bromo-4-chloro-indolyl-β-D-
galactopyranoside 
Competing interests 
The authors declare that they have no competing interests. 
Authors’ contributions 
TS and VWH conceived of the study, contributed to the study design, performed the data 
analyses, and prepared the manuscript. TS conducted the experiments. Both authors read and 
approved the final manuscript. 
Acknowledgements 
We wish to thank Mr. Bren Belovarac for his assistance with the qRT-PCR analysis of siAR- 
and siERα-transfected cells. This study was supported in part by a generous gift from the 
LIFE Foundation (Aspen, CO, USA), a Simons Foundation grant number 221192 (VWH), 
and an intramural grant from The George Washington University (Medical Faculty 
Associates award). We also thank Turner Biosystems (now Promega, Madison, WI, USA) for 
the gift of the Veritas microplate luminometer to VWH for her research on autism. None of 
the funding sources played any role in the study design, collection, analysis, and 
interpretation of data, writing of the manuscript, or decision to submit this study for 
publication. TS was a predoctoral student in the Institute for Biomedical Sciences at the 
George Washington University, who was supported by the Higher Educational Strategic 
Scholarship for Frontier Research Network (SFR scholarship) from the Office of the 
Commission on Higher Education of the Royal Thai Government, Thailand, through the 
Faculty of Allied Health Sciences, Chulalongkorn University. 
References 
1. American Psychiatric Association, American Psychiatric Association, Task Force on 
DSM-IV: Diagnostic and statistical manual of mental disorders: DSM-IV-TR: 4th edition, 
text revision ed. Washington, DC: American Psychiatric Association; 2000. 
2. Volkmar FR, Klin A, Siegel B, Szatmari P, Lord C, Campbell M, Freeman BJ, Cicchetti 
DV, Rutter M, Kline W: Field trial for autistic disorder in DSM-IV. Am J Psychiatry 1994, 
151:1361–1367. 
3. Kim YS, Leventhal BL, Koh Y, Fombonne E, Laska E, Lim E, Cheon K, Kim S, Kim Y, 
Lee H, Song D, Grinker RR: Prevalence of autism spectrum disorders in a total 
population sample. Am J Psychiatry 2011, 168:904–912. 
4. Mattila M, Kielinen M, Linna S, Jussila K, Ebeling H, Bloigu R, Joseph RM, Moilanen I: 
Autism spectrum disorders according to DSM-IV-TR and comparison with DSM-5 
draft criteria: An epidemiological study. J Am Acad Child Adolesc Psychiatry 2011, 
50:583–592. 
5. Fombonne E: Past and future perspectives on autism epidemiology. In Understanding 
autism: From basic neuroscience to treatment. Edited by Moldin SO, Rubenstein JL. Boca 
Raton, FL, USA: CRC Press; 2006:25–48. 
6. Baron-Cohen S, Knickmeyer RC, Belmonte MK: Sex differences in the brain: 
implications for explaining autism. Science 2005, 310:819–823. 
7. Auyeung B, Baron-Cohen S, Ashwin E, Knickmeyer R, Taylor K, Hackett G: Fetal 
testosterone and autistic traits. Br J Psychol 2009, 100:1–22. 
8. Auyeung B, Taylor K, Hackett G, Baron-Cohen S: Foetal testosterone and autistic traits 
in 18 to 24-month-old children. Mol Autism 2010, 1:11. 
9. Chura LR, Lombardo MV, Ashwin E, Auyeung B, Chakrabarti B, Bullmore ET, Baron-
Cohen S: Organizational effects of fetal testosterone on human corpus callosum size and 
asymmetry. Psychoneuroendocrinology 2010, 35:122–132. 
10. Lombardo MV, Ashwin E, Auyeung B, Chakrabarti B, Taylor K, Hackett G, Bullmore 
ET, Baron-Cohen S: Fetal testosterone influences sexually dimorphic gray matter in the 
human brain. J Neurosci 2012, 32:674–680. 
11. Hu VW, Nguyen A, Kim KS, Steinberg ME, Sarachana T, Scully MA, Soldin SJ, Luu T, 
Lee NH: Gene expression profiling of lymphoblasts from autistic and nonaffected sib 
pairs: altered pathways in neuronal development and steroid biosynthesis. PLoS One 
2009, 4:e5775–PLoS One. 
12. Nguyen A, Rauch TA, Pfeifer GP, Hu VW: Global methylation profiling of 
lymphoblastoid cell lines reveals epigenetic contributions to autism spectrum disorders 
and a novel autism candidate gene, RORA, whose protein product is reduced in autistic 
brain. FASEB J 2010, 24:3036–3051. 
13. Schrader M, Danielsson C, Wiesenberg I, Carlberg C: Identification of natural 
monomeric response elements of the nuclear receptor RZR/ROR. They also bind 
COUP-TF homodimers. J Biol Chem 1996, 271:19732–19736. 
14. Carlberg C, Hooft van Huijsduijnen R, Staple JK, DeLamarter JF, Becker-Andre M: 
RZRs, a new family of retinoid-related orphan receptors that function as both 
monomers and homodimers. Mol Endocrinol 1994, 8:757–770. 
15. Hu VW, Sarachana T, Kim KS, Nguyen A, Kulkarni S, Steinberg ME, Luu T, Lai Y, Lee 
NH: Gene expression profiling differentiates autism case-controls and phenotypic 
variants of autism spectrum disorders: evidence for circadian rhythm dysfunction in 
severe autism. Autism Res 2009, 2:78–97. 
16. Sarachana T, Xu M, Wu RC, Hu VW: Sex hormones in autism: androgens and 
estrogens differentially and reciprocally regulate RORA, a novel candidate gene for 
autism. PLoS One 2011, 6:e17116. 
17. Boukhtouche F, Janmaat S, Vodjdani G, Gautheron V, Mallet J, Dusart I, Mariani J: 
Retinoid-related orphan receptor alpha controls the early steps of Purkinje cell 
dendritic differentiation. J Neurosci 2006, 26:1531–1538. 
18. Hadj-Sahraoui N, Frederic F, Zanjani H, Delhaye-Bouchaud N, Herrup K, Mariani J: 
Progressive atrophy of cerebellar Purkinje cell dendrites during aging of the 
heterozygous staggerer mouse (Rora(+/sg)). Brain Res Dev Brain Res 2001, 126:201–209. 
19. Gold DA, Gent PM, Hamilton BA: ROR alpha in genetic control of cerebellum 
development: 50 staggering years. Brain Res 2007, 1140:19–25. 
20. Harding HP, Atkins GB, Jaffe AB, Seo WJ, Lazar MA: Transcriptional activation and 
repression by RORalpha, an orphan nuclear receptor required for cerebellar 
development. Mol Endocrinol 1997, 11:1737–1746. 
21. Boukhtouche F, Vodjdani G, Jarvis CI, Bakouche J, Staels B, Mallet J, Mariani J, 
Lemaigre-Dubreuil Y, Brugg B: Human retinoic acid receptor-related orphan receptor 
alpha1 overexpression protects neurones against oxidative stress-induced apoptosis. J 
Neurochem 2006, 96:1778–1789. 
22. Delerive P, Monte D, Dubois G, Trottein F, Fruchart-Najib J, Mariani J, Fruchart JC, 
Staels B: The orphan nuclear receptor ROR alpha is a negative regulator of the 
inflammatory response. EMBO Rep 2001, 2:42–48. 
23. Sato TK, Panda S, Miraglia LJ, Reyes TM, Rudic RD, McNamara P, Naik KA, 
FitzGerald GA, Kay SA, Hogenesch JB: A functional genomics strategy reveals Rora as a 
component of the mammalian circadian clock. Neuron 2004, 43:527–537. 
24. Fatemi SH, Aldinger KA, Ashwood P, Bauman ML, Blaha CD, Blatt GJ, Chauhan A, 
Chauhan V, Dager SR, Dickson PE, Estes AM, Goldowitz D, Heck DH, Kemper TL, King 
BH, Martin LA, Millen KJ, Mittleman G, Mosconi MW, Persico AM, Sweeney JA, Webb SJ, 
Welsh JP: Consensus paper: pathological role of the cerebellum in autism. Cerebellum 
2012, 11:777–807. 
25. Whitney ER, Kemper TL, Rosene DL, Bauman ML, Blatt GJ: Density of cerebellar 
basket and stellate cells in autism: evidence for a late developmental loss of Purkinje 
cells. J Neurosci Res 2009, 87:2245–2254. 
26. Vargas DL, Nascimbene C, Krishnan C, Zimmerman AW, Pardo CA: Neuroglial 
activation and neuroinflammation in the brain of patients with autism. Ann Neurol 2005, 
57:67–81. 
27. Chauhan A, Chauhan V: Oxidative stress in autism. Pathophysiology 2006, 13:171–
181. 
28. Kotagal S, Broomall E: Sleep in children with autism spectrum disorder. Pediatr 
Neurol 2012, 47:242–251. 
29. Glickman G: Circadian rhythms and sleep in children with autism. Neurosci Biobehav 
Rev 2010, 34:755–768. 
30. Johnson KP, Malow BA: Sleep in children with autism spectrum disorders. Curr Treat 
Options Neurol 2008, 10:350–359. 
31. Bourgeron T: The possible interplay of synaptic and clock genes in autism spectrum 
disorders. Cold Spring Harb Symp Quant Biol 2007, 72:645–654. 
32. Melke J, GoubranBotros H, Chaste P, Betancur C, Nygren G, Anckarsater H, Rastam M, 
Stahlberg O, Gillberg IC, Delorme R, Chabane N, Mouren-Simeoni MC, Fauchereau F, 
Durand CM, Chevalier F, Drouot X, Collet C, Launay JM, Leboyer M, Gillberg C, 
Bourgeron T: Abnormal melatonin synthesis in autism spectrum disorders. Mol 
Psychiatry 2008, 13:90–98. 
33. Chaste P, Clement N, Mercati O, Guillaume JL, Delorme R, Botros HG, Pagan C, 
Perivier S, Scheid I, Nygren G, Anckarsater H, Rastam M, Stahlberg O, Gillberg C, Serrano 
E, Lemiere N, Launay JM, Mouren-Simeoni MC, Leboyer M, Gillberg C, Jockers R, 
Bourgeron T: Identification of pathway-biased and deleterious melatonin receptor 
mutants in autism spectrum disorders and in the general population. PLoS One 2010, 
5:e11495. 
34. Lalonde R, Strazielle C: Discrimination learning in Rora(sg) and Grid2(ho) mutant 
mice. Neurobiol Learn Mem 2008, 90:472–474. 
35. Goodall G, Gheusi G: Abnormal patterns of maze patrolling in the mutant mouse 
staggerer. Behav Neural Biol 1987, 47:307–320. 
36. Lalonde R, Botez MI, Boivin D: Object exploration in staggerer mutant mice. Physiol 
Behav 1987, 41:115–117. 
37. Lalonde R: Exploration and spatial learning in staggerer mutant mice. J Neurogenet 
1987, 4:285–291. 
38. Sarachana T, Hu VW: Genome-wide identification of transcriptional targets of 
RORA reveals direct regulation of multiple genes associated with autism spectrum 
disorder. Mol Autism 2013, 4:14. 
39. Garcia-Segura LM, Veiga S, Sierra A, Melcangi RC, Azcoitia I: Aromatase: a 
neuroprotective enzyme. Prog Neurobiol 2003, 71:31–41. 
40. Garcia-Segura LM: Aromatase in the brain: not just for reproduction anymore. J 
Neuroendocrinol 2008, 20:705–712. 
41. Yang S, He X, Miller D: Hydroxysteroid (17β) dehydrogenase X in human health and 
disease. Mol Cell Endocrinol 2011, 343:1–6. 
42. Doulazmi M, Frederic F, Lemaigre-Dubreuil Y, Hadj-Sahraoui N, Delhaye-Bouchaud N, 
Mariani J: Cerebellar Purkinje cell loss during life span of the heterozygous staggerer 
mouse (Rora(+)/Rora(sg)) is gender-related. J Comp Neurol 1999, 411:267–273. 
43. Janmaat S, Akwa Y, Doulazmi M, Bakouche J, Gautheron V, Liere P, Eychenne B, 
Pianos A, Luiten P, Groothuis T, Baulieu EE, Mariani J, Sherrard RM, Frederic F: Age-
related Purkinje cell death is steroid dependent: ROR alpha haplo-insufficiency impairs 
plasma and cerebellar steroids and Purkinje cell survival. Age (Dordr) 2011, 33:565–578. 
44. Rozen S, Skaletsky H: Primer3 on the WWW for general users and for biologist 
programmers. Methods Mol Biol 2000, 132:365–386. 
45. Farre D, Roset R, Huerta M, Adsuara JE, Rosello L, Alba MM, Messeguer X: 
Identification of patterns in biological sequences at the ALGGEN server: PROMO and 
MALGEN. Nucleic Acids Res 2003, 31:3651–3653. 
46. Messeguer X, Escudero R, Farre D, Nunez O, Martinez J, Alba MM: PROMO: 
detection of known transcription regulatory elements using species-tailored searches. 
Bioinformatics 2002, 18:333–334. 
47. Bryne JC, Valen E, Tang MH, Marstrand T, Winther O, da Piedade I, Krogh A, Lenhard 
B, Sandelin A: JASPAR, the open access database of transcription factor-binding 
profiles: new content and tools in the 2008 update. Nucleic Acids Res 2008, 36(Database 
issue):D102–D106. 
48. Baron-Cohen S: Autism: the empathizing-systemizing (E-S) theory. Ann N Y Acad Sci 
2009, 1156:68–80. 
49. Baron-Cohen S, Lombardo MV, Auyeung B, Ashwin E, Chakrabarti B, Knickmeyer R: 
Why are autism spectrum conditions more prevalent in males? PLoS Biol 2011, 
9:e1001081. 
50. Auyeung B, Baron-Cohen S, Chapman E, Knickmeyer R, Taylor K, Hackett G: Foetal 
testosterone and the child systemizing quotient. Eur J Endocrinol 2006, 155:S123–S130. 
51. McKenna NJ, O'Malley BW: Minireview: nuclear receptor coactivators–an update. 
Endocrinology 2002, 143:2461–2465. 
52. McKenna NJ, O'Malley BW: Combinatorial control of gene expression by nuclear 
receptors and coregulators. Cell 2002, 108:465–474. 
53. McKenna NJ, Cooney AJ, Demayo FJ, Downes M, Glass CK, Lanz RB, Lazar MA, 
Mangelsdorf DJ, Moore DD, Qin J, Steffen DL, Tsai M, Tsai SY, Yu R, Margolis RN, Evans 
RM, O'Malley BW: Minireview: evolution of NURSA, the Nuclear Receptor Signaling 
Atlas. Mol Endocrinol 2009, 23:740–746. 
54. Margolis RN, Evans RM, O'Malley BW: The Nuclear Receptor Signaling Atlas: 
development of a functional atlas of nuclear receptors. Mol Endocrinol 2005, 19:2433–
2436. 
55. Gill G: Something about SUMO inhibits transcription. Curr Opin Genet Dev 2005, 
15:536–541. 
56. Hay RT: SUMO: A history of modification. Mol Cell 2005, 18:1–12. 
57. Poukka H, Karvonen U, Janne OA, Palvimo JJ: Covalent modification of the androgen 
receptor by small ubiquitin-like modifier 1 (SUMO-1). Proc Natl Acad Sci U S A 2000, 
97:14145–14150. 
58. Sauve F, McBroom LD, Gallant J, Moraitis AN, Labrie F, Giguere V: CIA, a novel 
estrogen receptor coactivator with a bifunctional nuclear receptor interacting 
determinant. Mol Cell Biol 2001, 21:343–353. 
59. Xiong Z, Ding L, Sun J, Cao J, Lin J, Lu Z, Liu Y, Huang C, Ye Q: Synergistic 
repression of estrogen receptor transcriptional activity by FHL2 and Smad4 in breast 
cancer cells. IUBMB Life 2010, 62:669–676. 
60. Muller JM, Isele U, Metzger E, Rempel A, Moser M, Pscherer A, Breyer T, Holubarsch 
C, Buettner R, Schule R: FHL2, a novel tissue-specific coactivator of the androgen 
receptor. EMBO J 2000, 19:359–369. 
61. Lonard DM, Kumar R, O'Malley BW: Minireview: the SRC family of coactivators: an 
entree to understanding a subset of polygenic diseases? Mol Endocrinol 2010, 24:279–
285. 
62. Foulds CE, Feng Q, Ding C, Bailey S, Hunsaker TL, Malovannaya A, Hamilton RA, 
Gates LA, Zhang Z, Li C, Chan D, Bajaj A, Callaway CG, Edwards DP, Lonard DM, Tsai 
SY, Tsai MJ, Qin J, O'Malley BW: Proteomic analysis of coregulators bound to ERalpha 
on DNA and nucleosomes reveals coregulator dynamics. Mol Cell 2013, 51:185–199. 
63. Smith CL, O'Malley BW: Coregulator function: a key to understanding tissue 
specificity of selective receptor modulators. Endocr Rev 2004, 25:45–71. 
64. Gonzalez M, Cabrera-Socorro A, Perez-Garcia CG, Fraser JD, Lopez FJ, Alonso R, 
Meyer G: Distribution patterns of estrogen receptor alpha and beta in the human cortex 
and hippocampus during development and adulthood. J Comp Neurol 2007, 503:790–
802. 
65. Delaunay F, Pettersson K, Tujague M, Gustafsson JA: Functional differences between 
the amino-terminal domains of estrogen receptors alpha and beta. Mol Pharmacol 2000, 
58:584–590. 
66. Spampinato SF, Molinaro G, Merlo S, Iacovelli L, Caraci F, Battaglia G, Nicoletti F, 
Bruno V, Sortino MA: Estrogen receptors and type 1 metabotropic glutamate receptors 
are interdependent in protecting cortical neurons against beta-amyloid toxicity. Mol 
Pharmacol 2012, 81:12–20. 
67. Dubal DB, Zhu H, Yu J, Rau SW, Shughrue PJ, Merchenthaler I, Kindy MS, Wise PM: 
Estrogen receptor alpha, not beta, is a critical link in estradiol-mediated protection 
against brain injury. Proc Natl Acad Sci U S A 2001, 98:1952–1957. 
68. Choleris E, Ogawa S, Kavaliers M, Gustafsson JA, Korach KS, Muglia LJ, Pfaff DW: 
Involvement of estrogen receptor alpha, beta and oxytocin in social discrimination: A 
detailed behavioral analysis with knockout female mice. Genes Brain Behav 2006, 5:528–
539. 
69. Purves D, Augustine GJ, Fitzpatrick D, Hall WC, LaMantia A, White LE: In 
Neuroscience. 5th edition. Edited by Purves D, Augustine GJ, Fitzpatrick D, Hall WC, 
LaMantia A, White LE. Sunderland, MA: Sinauer Associates, Inc; 2012:669–694. 
Additional files 
Additional_file_1 as DOC 
Additional file 1. List of antibodies and siRNAs used in this study. 
Additional_file_2 as DOC 
Additional file 2. Transfection efficiency of siRNAs. 
Additional_file_3 as DOC 
Additional file 3. List of primers for PCR cloning, ChIP-reChIP-qPCR, and qRT-PCR 
analyses. 
Additional_file_4 as DOC 
Additional file 4. Transcription factor binding sites in promoter regions of RORA and 
CYP19A1 genes. 
Additional_file_5 as DOC 
Additional file 5. Nuclear receptor coregulators found to be dysregulated in LCLs from 









Additional files provided with this submission:
Additional file 1: 5743049121052997_add1.doc, 38K
http://www.molecularautism.com/imedia/2008919294110105/supp1.doc
Additional file 2: 5743049121052997_add2.doc, 109K
http://www.molecularautism.com/imedia/1598982152110105/supp2.doc
Additional file 3: 5743049121052997_add3.doc, 26K
http://www.molecularautism.com/imedia/4047653611101052/supp3.doc
Additional file 4: 5743049121052997_add4.doc, 37K
http://www.molecularautism.com/imedia/1982013481110105/supp4.doc
Additional file 5: 5743049121052997_add5.doc, 44K
http://www.molecularautism.com/imedia/1474782038110105/supp5.doc
